Equillium to Present at Investor Conferences in November 2020
Equillium, Inc. (Nasdaq: EQ) announced that CEO Bruce Steel and CMO Krishna Polu, M.D., will present at two investor conferences in November 2020. The first event is the Stifel 2020 Virtual Healthcare Conference on November 18 at 3:20 PM ET, followed by the Jefferies Virtual London Healthcare Conference on November 19 at 6:10 PM GMT. Live webcasts will be accessible on Equillium's website, with replays available for 30 days. The company is focused on developing its lead product, itolizumab, for various severe autoimmune diseases.
- None.
- None.
LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equillium’s chief executive officer and Krishna Polu, M.D., Equillium’s chief medical officer, will present at two upcoming investor conferences in November 2020.
| Event: Date: Time: Location: | Stifel 2020 Virtual Healthcare Conference Wednesday, November 18, 2020 3:20 PM Eastern Time | 12:20 PM Pacific Time Virtual Webcast |
| Event: Date: Time: Location: | Jefferies Virtual London Healthcare Conference Thursday, November 19, 2020 6:10 PM GMT | 1:10 PM Eastern Time | 10:10 AM PM Pacific Time Virtual Webcast |
Live webcasts of both presentations will be available under the “Investors” section of the Company’s website at https://ir.equilliumbio.com/. Replays will be available for 30 days following each webcast.
About Itolizumab
Itolizumab is a clinical-stage, first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Itolizumab is currently being evaluated in multiple clinical trials in patients with severe diseases, including aGVHD, lupus nephritis, uncontrolled asthma, and will soon be evaluated in a clinical trial of patients with COVID-19. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited. Itolizumab is marketed in India under the trade name “ALZUMAb-L” for the treatment of chronic plaque psoriasis and has received emergency use approval in India to treat cytokine release syndrome in COVID-19 patients with moderate to severe acute respiratory distress syndrome.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including COVID-19, aGVHD, lupus nephritis and uncontrolled asthma.
For more information, visit www.equilliumbio.com.
Investor Contact
Christine Zedelmayer, Chief Operating Officer
+1-858-412-5302
ir@equilliumbio.com
Media Contact
Katherine Carlyle Smith
Senior Account Associate
Canale Communications
+1-805-907-2497
katherine.smith@canalecomm.com
FAQ
When will Equillium present at the Stifel 2020 Virtual Healthcare Conference?
What is the date and time of Equillium's presentation at the Jefferies Virtual London Healthcare Conference?
Where can I watch the live presentation of Equillium?
What is itolizumab and what diseases is it targeting?
How long will replays of Equillium's presentations be available?
